Imatinib mesylate tablet and preparation method thereof

Abstract

The invention discloses an imatinib mesylate tablet and a preparation method thereof. The imatinib mesylate tablet comprises 8-30% of crospovidone and 8 to 40% of silica. The preparation method comprises the following steps of carrying out granulation of imatinib mesylate and a waterless organic solvent, drying the granules, uniformly mixing the granules, crospovidone, silica, a filler and a lubricant, and carrying out tabletting. The preparation method solves the problem of a slow dissolution rate of a preparation obtained by the prior art.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to imatinib mesylate tablets and a preparation method thereof. Background technique [0002] Imatinib mesylate is a selective tyrosine kinase inhibitor developed by Swiss Novartis, which belongs to the anilinoquinazoline compounds. It was approved by FDA in May 2001 for the treatment of chronic myelogenous leukemia. In February 2002, FDA further approved imatinib mesylate for the treatment of gastrointestinal stromal tumors. Imatinib mesylate can inhibit Bcr-Abl tyrosine kinase at the cellular level in vivo and in vitro, and can selectively inhibit Bcr-Abl positive cell line cells, Ph chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia Proliferation and induction of apoptosis in fresh cells from patients. In addition, imatinib mesylate can also inhibit platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), ...

Images